Home・Stock List・Novavax Inc

Novavax Inc

Closed

SectorHealthcare

7.65 3.1

Buy Sell

Overview

Share price change

24h

Current

Min

7.4

Max

7.6899999999999995

Key metrics
By Trading Economics
Income	-27M -9.5M
Sales	-7.6M 140M
P/E Sector Avg	3.112 64.641
EPS	-0.06
Profit margin	-6.803
Employees	749
EBITDA	-29M -543K

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+45.07% upside

Dividends
By Acuity
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-89M 1.2B
Previous open	4.55
Previous close	7.65

News Sentiment

By Acuity

50%

151 / 340 Healthcare

Novavax Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31 Jul 2026, 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30 Jul 2026, 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29 Jul 2026, 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28 Jul 2026, 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27 Jul 2026, 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24 Jul 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23 Jul 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22 Jul 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21 Jul 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20 Jul 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Peer Comparison

Price change

Novavax Inc Forecast

Price Target

By TipRanks

45.07% upside

12 Months Forecast

Average 10.75 USD 45.07%

High 19 USD

Low 7 USD

Based on 4 Wall Street analysts offering 12 month price targets forNovavax Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Novavax Inc - Dist in the past 3 months.

Sentiment

By Acuity

151 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.